Your browser doesn't support javascript.
loading
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods.
Mostofian, Barmak; Martin, Holli-Joi; Razavi, Asghar; Patel, Shivam; Allen, Bryce; Sherman, Woody; Izaguirre, Jesus A.
Afiliación
  • Mostofian B; OpenEye, Cadence Molecular Sciences, Boston, Massachusetts 02114 United States.
  • Martin HJ; Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599 United States.
  • Razavi A; ENKO Chem, Inc, Mystic, Connecticut 06355 United States.
  • Patel S; Psivant Therapeutics, Boston, Massachusetts 02210 United States.
  • Allen B; Differentiated Therapeutics, San Diego, California 92056 United States.
  • Sherman W; Psivant Therapeutics, Boston, Massachusetts 02210 United States.
  • Izaguirre JA; Differentiated Therapeutics, San Diego, California 92056 United States.
J Chem Inf Model ; 63(17): 5408-5432, 2023 09 11.
Article en En | MEDLINE | ID: mdl-37602861
ABSTRACT
The therapeutic approach of targeted protein degradation (TPD) is gaining momentum due to its potentially superior effects compared with protein inhibition. Recent advancements in the biotech and pharmaceutical sectors have led to the development of compounds that are currently in human trials, with some showing promising clinical results. However, the use of computational tools in TPD is still limited, as it has distinct characteristics compared with traditional computational drug design methods. TPD involves creating a ternary structure (protein-degrader-ligase) responsible for the biological function, such as ubiquitination and subsequent proteasomal degradation, which depends on the spatial orientation of the protein of interest (POI) relative to E2-loaded ubiquitin. Modeling this structure necessitates a unique blend of tools initially developed for small molecules (e.g., docking) and biologics (e.g., protein-protein interaction modeling). Additionally, degrader molecules, particularly heterobifunctional degraders, are generally larger than conventional small molecule drugs, leading to challenges in determining drug-like properties like solubility and permeability. Furthermore, the catalytic nature of TPD makes occupancy-based modeling insufficient. TPD consists of multiple interconnected yet distinct steps, such as POI binding, E3 ligase binding, ternary structure interactions, ubiquitination, and degradation, along with traditional small molecule properties. A comprehensive set of tools is needed to address the dynamic nature of the induced proximity ternary complex and its implications for ubiquitination. In this Perspective, we discuss the current state of computational tools for TPD. We start by describing the series of steps involved in the degradation process and the experimental methods used to characterize them. Then, we delve into a detailed analysis of the computational tools employed in TPD. We also present an integrative approach that has proven successful for degrader design and its impact on project decisions. Finally, we examine the future prospects of computational methods in TPD and the areas with the greatest potential for impact.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Chem Inf Model Asunto de la revista: INFORMATICA MEDICA / QUIMICA Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Productos Biológicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: J Chem Inf Model Asunto de la revista: INFORMATICA MEDICA / QUIMICA Año: 2023 Tipo del documento: Article
...